REG - IXICO plc - Extension of Huntington's disease consortium

IXICOAnnouncement

03/04/2023 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230403:nRSC1157Va&default-theme=true

RNS Number : 1157V  IXICO plc  03 April 2023

3 April 2023

 

IXICO plc

("IXICO" or the "Company")

 

Extension of Huntington's disease consortium worth circa £1 million

 

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO)
delivering advanced AI analytical insights in neuroscience, is pleased to
announce it has secured additional contract orders to support completion of
the retrospective analysis of over 6,000 HD imaging datasets through the
Huntington's Disease Imaging Harmonization Consortium (HD-IH), previously
announced on 21(st) September 2022.  HD is a rare, inherited
neurodegenerative disease that causes the progressive breakdown of nerve cells
in the brain affecting movement, mood and thinking abilities. There are no
existing approved disease modifying therapies for HD, nor interventions that
slow disease progression.

 

The output of the project will enable current and prospective consortium
partners together with their collaborators to develop improved approaches to
stratifying patients in HD clinical trials as well as increasing the precision
of efficacy measurements of drugs within HD clinical trials.  IXICO is
delivering this analysis to the biopharma and charitable foundation consortium
members using its proprietary, deep learning based, IXIQ.Ai analysis platform.
Additional financial contribution has been secured from two partners, where
one is a new consortium member and the other, an existing consortium member,
enabling completion by June 2025. The consortium partners remain open for
additional partners to join to benefit from the analysis already undertaken
and to further accelerate completion of the project.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "The HD-IH
consortium is working on the development of new standards for imaging in HD
through the analysis and interpretation of existing HD imaging datasets.  We
are very excited to build additional momentum in the consortium and look
forward to working closely with our existing and new partners towards the
development of novel imaging tools that enable the design of more efficient HD
clinical trials.

 

The development of new imaging standards in this consortium further cements
IXICO's position as the leading analysis company for HD as part of its wider
portfolio of leading analytical tools to support clinical trials into
neurological diseases."

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning Ai data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTSSESWDEDSEDL